NASDAQ: VYNEVyne Therapeutics Inc Stock
$1.85+0.04 (+2.21%)
Updated Apr 17, 2025
VYNE Price
$1.85
Fair Value Price
$0.43
Market Cap
$28.14M
52 Week Low
$1.44
52 Week High
$4.30
P/E
-1.99x
P/B
0.54x
P/S
284.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$501.00k
Earnings
-$39.83M
Gross Margin
100%
Operating Margin
-7,950.1%
Profit Margin
-7,950.9%
Debt to Equity
0.29
Operating Cash Flow
-$34M
Beta
1.15
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
VYNE Overview
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VYNE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VYNE
Ranked#275 of 463
Ranked#275 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important VYNE news, forecast changes, insider trades & much more!
VYNE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VYNE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VYNE ($1.85) is overvalued by 329.5% relative to our estimate of its Fair Value price of $0.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VYNE ($1.85) is not significantly undervalued (329.5%) relative to our estimate of its Fair Value price of $0.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VYNE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VYNE due diligence checks available for Premium users.
Valuation
VYNE fair value
Fair Value of VYNE stock based on Discounted Cash Flow (DCF)
Price
$1.85
Fair Value
$0.43
Overvalued by
329.50%
VYNE ($1.85) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VYNE ($1.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VYNE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VYNE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.99x
Industry
-177.72x
Market
27.98x
VYNE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.54x
Industry
4.05x
VYNE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VYNE's financial health
Profit margin
Revenue
$84.0k
Net Income
-$12.0M
Profit Margin
-14,311.9%
VYNE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VYNE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$66.9M
Liabilities
$14.8M
Debt to equity
0.29
VYNE's short-term assets ($64.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VYNE's short-term assets ($64.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VYNE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VYNE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.0M
Investing
$12.7M
Financing
-$132.0k
VYNE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VYNE vs Biotech Stocks
Vyne Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.